DRD2 and glioblastoma: Computer-assisted structure characterization and target prediction partly based on the broadly-used “scaffold identification” and “ligand-based” chemical fingerprint strategy was used to identify proteins with known ligands similar to our query molecule [21], and predict LCC-09 targets dopamine receptors DRD1, DRD2, DRD3, and DRD4 (Figure 1C), as well as oncogenic markers implicated in GBM metastatic and recurrent phenotype including EGFR, Akt, mTOR, Erk1/2, NF-κB, c-Myc, β-catenin, CDK6, and EZH2 (Figure 1D).